Company Description
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases.
Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration initially in Duchenne muscular dystrophy (“DMD”).
Satellos has generated evidence in preclinical models of DMD to support its hypothesis that correcting muscle stem cell polarity through treatment with SAT-3247 has the potential to restore skeletal muscle regeneration, thereby enhancing repair and increasing muscle strength.
SAT-3247 is the Company’s lead drug candidate. SAT-3247 is currently in clinical development in two clinical trials.
Additionally, Satellos continues to leverage its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases where deficits in muscle regeneration may occur that are amenable to therapeutic intervention for future development.
| Country | Canada |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Frank Gleeson, MBA |
Contact Details
Address: Royal Bank Plaza, South Tower, 200 Bay Street, Suite 2800 Toronto, ON M5J 2J3 Canada | |
| Phone | (647) 660-1780 |
| Website | satellos.com |
Stock Details
| Ticker Symbol | MSLE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1421642 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Geoff MacKay | Non-Executive Director and Chairman |
| Franklin Berger, CFA | Non-Executive Director |
| Brian Bloom | Non-Executive Director |
| Stephanie Brown, MBA | Non-Executive Director |
| Iris Loew-Friedrich, M.D., Ph.D. | Non-Executive Director |
| Selwyn Ho, MBBS | Non-Executive Director |
| Frank Gleeson, MBA | President, Chief Executive Officer, and Director |
| Adam Mostafa | Non-Executive Director |
| Mark Nawacki, MBA CPA | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2026 | 6-K | Report of foreign issuer |
| Feb 10, 2026 | 6-K | Report of foreign issuer |
| Feb 10, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | SUPPL | Filing |
| Feb 6, 2026 | CERT | Certification by an exchange approving securities for listing |
| Feb 5, 2026 | 8-A12B | Registration of securities |
| Feb 5, 2026 | F-X | Filing |
| Feb 5, 2026 | F-10 | Filing |
| Jan 3, 2025 | D | Notice of Exempt Offering of Securities |